skin disease: Any deviation from the normal structure or function of the skin or subcutaneous tissue that is manifested by a characteristic set of symptoms and signs.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
508 |
4. Check minimum number of eventsNone |
508 |
5. Include endpointsNone |
508 |
6. Filter based on genotype QC (FinnGen only) |
508 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L85
- Name in latin
- Xerosis cutis
Similar endpoints
↥List of similar endpoints to
Xerosis cutis
based on the number of shared cases.
Similar with more cases:
- Other epidermal thickening
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2572 | 1334 | 1230 |
| Only index persons | 2357 | 1230 | 1127 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.03 |
| Only index persons | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 68.29 | 67.94 | 68.83 |
| Only index persons | 68.76 | 68.34 | 69.22 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 508 | 252 | 256 |
| Unadjusted period prevalence (%) | 0.10 | 0.09 | 0.11 |
| Median age at first event (years) | 69.33 | 66.46 | 72.15 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 440
- Matched controls
- 4401
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L85.3
ICD-10 Finland
Xerosis cutis
+∞
323.0
440
11
E0000UV
ATC
NA
9.0
94.9
334
1136
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
10.8
68.0
143
187
L30.9
ICD-10 Finland
Dermatitis, unspecified
6.5
58.1
183
434
QXA25
NOMESCO Finland
Destruction of lesion of skin, site unspecified
22.5
56.3
83
45
TQW80
NOMESCO Finland
Local dermatologic skincare
19.3
46.6
72
44
L85.89
ICD-10 Finland
Other specified epidermal thickening
484.2
45.1
44
*
L84
ICD-10 Finland
Corns and callosities
20.0
44.0
67
39
D07AC01
ATC
betamethasone; topical
3.9
39.0
235
997
R4180
NOMESCO Finland
Podiatric therapy
46.5
38.0
46
11
L30.4
ICD-10 Finland
Erythema intertrigo
73.0
35.6
40
6
L57.0
ICD-10 Finland
Actinic keratosis
6.1
35.4
106
217
L98.4
ICD-10 Finland
Chronic ulcer of skin, not elsewhere classified
43.9
32.7
40
10
D07AB08
ATC
desonide; topical
5.2
29.6
102
243
E000001
ATC
NA
3.8
29.3
151
530
SPAT1148
SPAT
Treatment of chronic ulcer or burn
4.4
28.9
118
335
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
39.0
28.8
36
10
SPAT1144
SPAT
Treatment of reopened or infected surgical wound
6.5
27.7
76
136
S18
ICPC
Laceration/cut
3.0
26.5
244
1290
SPAT1156
SPAT
Guidance concerning treatment of rash and skin
4.1
26.1
118
364
L82
ICD-10 Finland
Seborrhoeic keratosis
4.2
24.9
107
314
H02AB06
ATC
prednisolone; systemic
2.8
24.3
257
1455
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
5.5
24.1
76
161
D02AE01
ATC
carbamide; topical
5.9
23.5
69
134
D07AB02
ATC
hydrocortisone butyrate; topical
3.1
23.5
169
741
L29.9
ICD-10 Finland
Pruritus, unspecified
12.1
22.9
42
38
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
4.4
22.4
88
235
B35.1
ICD-10 Finland
Tinea unguium
7.1
22.1
56
89
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.8
21.6
197
994
SPAT1153
SPAT
Removal of sutures
2.7
21.0
192
966
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
20.9
246
1433
SPAT1149
SPAT
Suture or treatment of traumatic wound
3.7
20.5
101
330
D07BB04
ATC
hydrocortisone butyrate and antiseptics; topical
3.8
20.4
95
296
SPAT1301
SPAT
No procedures
2.6
18.9
190
993
-
ICD-10 Finland
NA
10.8
18.8
36
36
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
18.3
171
853
C03CA01
ATC
furosemide; systemic
2.6
18.1
180
927
R23.8
ICD-10 Finland
Other and unspecified skin changes
3.4
17.4
95
332
S97
ICPC
Chronic ulcer skin
5.9
17.2
49
91
L04AA06
ATC
mycophenolic acid; systemic
17.2
16.7
26
16
L30.8
ICD-10 Finland
Other specified dermatitis
10.7
16.7
32
32
J01DB01
ATC
cefalexin; oral
2.8
16.1
374
2933
D01AC20
ATC
imidazoles/triazoles in combination with corticosteroids; topical
2.7
15.3
129
593
A46
ICD-10 Finland
Erysipelas
3.1
15.1
92
345
SPAT1249
SPAT
Treatment-related counselling outside office
2.3
15.0
207
1231
TK800
NOMESCO Finland
Hemodialysis
11.9
15.0
27
24
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.1
14.9
90
334
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
5.7
14.8
43
82
XPX99
NOMESCO Finland
Other diagnostic examination of periferal vessel
4.6
14.8
53
128
SPAT1312
SPAT
General health counselling
2.4
14.6
171
935
127
Kela drug reimbursment
Transplant complication
16.1
14.6
23
15
RJ410
NOMESCO Finland
NA
154.9
14.5
15
*
SPAT1292
SPAT
Other function in accordance with SHToL (Finnish classification of nursing interventions)
3.6
14.4
68
211
B35.3
ICD-10 Finland
Tinea pedis
5.9
14.3
40
73
L30.3
ICD-10 Finland
Infective dermatitis
6.5
14.3
37
61
NH3BG
NOMESCO Finland
MRI of foot
44.0
14.2
17
*
SPAT1225
SPAT
Implementation of podiatry rehabilitation plan
7.9
14.2
32
43
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
4.2
14.1
56
149
N02BE01
ATC
paracetamol; systemic, rectal
3.1
14.1
396
3280
D02AX
ATC
Other emollients and protectives
8.3
14.1
31
40
NH3CG
NOMESCO Finland
Extensive MRI of foot
55.2
13.9
16
*
N02AJ06
ATC
codeine and paracetamol; systemic
2.2
13.7
182
1051
Z94.0
ICD-10 Finland
Kidney transplant status
19.0
13.5
20
11
E000006
ATC
NA
4.0
13.5
56
156
L20.9
ICD-10 Finland
Atopic dermatitis, unspecified
8.0
13.4
30
40
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
5.5
13.2
39
76
B07.9
ICD-10 Finland
Verruca simplex
6.8
13.2
33
52
J01MA02
ATC
ciprofloxacin; systemic
2.2
13.0
198
1208
XQ848
NOMESCO Finland
Dermatological photography
9.5
12.9
26
29
L21.8
ICD-10 Finland
Other seborrhoeic dermatitis
14.6
12.9
21
15
SPAT1253
SPAT
Initiation, adjustment, discontinuation or repetition of medication
2.2
12.8
165
929
L04AD01
ATC
ciclosporin; systemic
10.5
12.6
24
24
D07AA02
ATC
hydrocortisone; topical
2.9
12.6
82
319
SPAT1263
SPAT
Sampling
2.1
12.6
210
1328
D07AC13
ATC
mometasone; topical
2.3
12.5
147
793
RJ190
NOMESCO Finland
NA
133.6
12.5
13
*
RJ421
NOMESCO Finland
NA
38.7
12.3
15
*
D01AE16
ATC
amorolfine; topical
3.0
12.2
76
285
D05BB02
ATC
acitretin; oral
9.7
12.1
24
26
C44.31
ICD-10 Finland
Basocellular carcinoma of the skin on another or unspecified part of the face
4.1
12.1
48
128
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
7.9
12.1
27
36
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
22.0
12.1
17
8
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.2
12.1
154
860
H02AB04
ATC
methylprednisolone; systemic
2.8
11.9
82
331
D07AD01
ATC
clobetasol; topical
2.8
11.8
84
343
RJ411
NOMESCO Finland
NA
31.0
11.7
15
5
R60.0
ICD-10 Finland
Localized oedema
2.9
11.4
74
288
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
7.6
11.4
26
36
UJF32
NOMESCO Finland
Coloscopy
2.2
11.4
143
791
C44.51
ICD-10 Finland
Basocellular carcinoma of the skin on the torso
5.7
11.3
32
60
J01FF01
ATC
clindamycin; systemic
2.2
11.2
132
708
A02BC02
ATC
pantoprazole; systemic
2.0
11.0
301
2270
D07BA04
ATC
hydrocortisone and antiseptics; topical
3.0
10.9
65
237
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
28.8
10.8
14
5
PD4CC
NOMESCO Finland
Very extensive arterigography of lower extremity with X-ray
22.1
10.7
15
7
R06AX27
ATC
desloratadine; oral
2.3
10.7
117
601
R06AE07
ATC
cetirizine; oral
2.0
10.4
191
1225
E000003
ATC
NA
4.6
10.3
35
81
L17
ICPC
Foot/toe symptom/complaint
2.2
10.3
127
691
E10.7
ICD-10 Finland
Type 1 diabetes mellitus, With multiple complications
7.9
10.0
22
29
NHQ40
NOMESCO Finland
Amputation of toe
17.2
9.9
15
9
N08.39*E10.2
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic nephropathy
26.7
9.9
13
5
SPAT1255
SPAT
Intravenous administration of medicine
3.6
9.8
44
131
D07BC01
ATC
betamethasone and antiseptics; topical
2.7
9.8
70
287
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
2.7
9.8
70
288
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.8
9.6
40
112
SPAT1254
SPAT
Administration of medicine
2.4
9.6
85
392
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.0
9.6
56
203
E000002
ATC
NA
2.8
9.6
64
253
L04AX01
ATC
azathioprine; systemic
5.2
9.6
29
59
SPAT1310
SPAT
Counselling related to known health issue
2.0
9.6
155
941
N03AX12
ATC
gabapentin; oral
2.5
9.5
82
375
PF1AT
NOMESCO Finland
Intravascular dilatation of arteries of knee, lower leg and ankle (PTA)
30.7
9.4
12
*
A12AA04
ATC
calcium carbonate; oral
8.3
9.4
20
25
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
12.7
9.4
16
13
RJ422
NOMESCO Finland
NA
+∞
9.4
9
*
WXQ27
NOMESCO Finland
UVB narrow spectrum light therapy
11.0
9.4
17
16
WZB00
NOMESCO Finland
Telephone receipt or other advice
2.1
9.3
131
748
SPAT1210
SPAT
Application of cast or individual aid
4.8
9.3
30
66
T81.4
ICD-10 Finland
Infection following a procedure, not elsewhere classified
3.0
9.3
56
205
TNX92
NOMESCO Finland
Supporting bandage or orthosis of lower limb
8.0
9.2
20
26
R07.4
ICD-10 Finland
Chest pain, unspecified
2.0
9.2
143
850
JN3BD
NOMESCO Finland
Extensive abdominal CT
2.7
9.2
64
259
D22.9
ICD-10 Finland
Melanocytic naevi, unspecified
5.3
9.1
27
54
J01MA14
ATC
moxifloxacin; systemic
3.0
9.0
55
203
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.9
8.9
186
1233
CJE20
NOMESCO Finland
Phakoemulsification with implantation of artificial lens in posterior chamber
1.9
8.9
163
1031
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.2
8.7
93
472
SPAT1325
SPAT
Vaccination
1.9
8.7
175
1142
D06BX01
ATC
metronidazole; topical
2.9
8.6
54
205
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.4
8.6
41
129
H36.03
ICD-10 Finland
Proliferative diabetic retinopathy
16.7
8.6
13
8
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
6.6
8.6
21
33
Z01.8
ICD-10 Finland
Other specified special examinations
2.1
8.6
104
558
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.8
8.6
54
206
M79.6
ICD-10 Finland
Pain in limb
1.9
8.6
163
1040
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.8
8.5
193
1311
P01AB01
ATC
metronidazole; oral, rectal
1.9
8.4
173
1131
RJ511
NOMESCO Finland
NA
91.7
8.4
9
*
L85.9
ICD-10 Finland
Epidermal thickening, unspecified
91.7
8.4
9
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.1
8.4
47
165
I70.2
ICD-10 Finland
Atherosclerosis of arteries of extremities
2.7
8.3
56
222
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
3.4
8.3
39
121
SPAT1216
SPAT
Assessment of functional ability
2.2
8.3
86
429
M54.5
ICD-10 Finland
Low back pain
1.9
8.0
148
931
R06.0
ICD-10 Finland
Dyspnoea
2.0
8.0
122
716
A41.9
ICD-10 Finland
Sepsis, unspecified
4.8
7.9
25
54
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.2
7.9
29
73
SPAT1101
SPAT
Orthostatic test
3.4
7.9
37
115
L20.0
ICD-10 Finland
Besnier prurigo
3.6
7.9
34
99
V03AE01
ATC
polystyrene sulfonate; oral
8.7
7.9
16
19
SPAT1260
SPAT
Consultation of another employee
2.2
7.9
89
460
T89
ICPC
Diabetes insulin dependent
4.4
7.9
27
64
L04AA01
ATC
[U] ciclosporin; systemic
11.1
7.8
14
13
R22.4
ICD-10 Finland
Localized swelling, mass and lump, lower limb
6.1
7.8
20
34
137
Kela drug reimbursment
Uraemia requiring dialysis
15.4
7.8
12
8
E10.2
ICD-10 Finland
Type 1 diabetes mellitus, With renal complications
15.4
7.8
12
8
C44.81
ICD-10 Finland
Overall basocellular carcinoma of the skin
15.4
7.8
12
8
L29.8
ICD-10 Finland
Other pruritus
7.6
7.7
17
23
G63.2*E10.4
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic polyneuropathy
45.8
7.7
9
*
B03XA02
ATC
darbepoetin alfa; parenteral
6.9
7.7
18
27
L30.0
ICD-10 Finland
Nummular dermatitis
4.5
7.7
26
61
E10.6
ICD-10 Finland
Type 1 diabetes mellitus, With other specified complications
18.7
7.6
11
6
B05DA
ATC
Isotonic solutions
18.7
7.6
11
6
C10AX09
ATC
ezetimibe; oral
2.5
7.6
60
259
KA2AT
NOMESCO Finland
Biopsy of transplanted kidney with ultrasound guidance
25.5
7.6
10
*
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
1.8
7.5
150
965
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
1.9
7.5
123
735
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
2.7
7.4
50
198
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.4
7.4
64
290
WKPAL
NOMESCO Finland
NA
8.6
7.4
15
18
C07AB07
ATC
bisoprolol; oral
1.7
7.4
223
1633
Z94.1
ICD-10 Finland
Heart transplant status
+∞
7.3
7
*
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic (ophth., corticosteroids and antiinfectives in comb.)
1.8
7.3
168
1131
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
2.6
7.3
53
221
J01CE02
ATC
phenoxymethylpenicillin; oral
1.7
7.2
282
2223
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
2.6
7.2
52
213
B05DB
ATC
Hypertonic solutions
20.4
7.2
10
5
A02BC03
ATC
lansoprazole; oral
1.8
7.1
141
901
R22.0
ICD-10 Finland
Localized swelling, mass and lump, head
4.3
7.1
25
61
AA1AD
NOMESCO Finland
CT of head and brain
1.9
7.1
123
750
E000007
ATC
NA
3.4
7.1
33
103
L08.8
ICD-10 Finland
Other specified local infections of skin and subcutaneous tissue
5.1
7.1
21
43
A10AE04
ATC
insulin glargine; parenteral
2.5
7.0
54
230
E10.3
ICD-10 Finland
Type 1 diabetes mellitus, With ophthalmic complications
5.3
7.0
20
39
SAB01
NOMESCO Finland
Restricted oral and dental health check by dental hygienist or dental assistant
2.8
7.0
42
157
K21.0
ICD-10 Finland
Gastro-oesophageal reflux disease with oesophagitis
2.5
6.9
56
245
J01AA02
ATC
doxycycline; systemic
1.8
6.9
331
2761
CKD65
NOMESCO Finland
Pars plana or pars plicata vitrectomy
5.2
6.9
20
40
Z49.1
ICD-10 Finland
Extracorporeal dialysis
8.5
6.9
14
17
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
6.3
6.8
17
28
H36.09*E10.3
ICD-10 Finland
Insulin-dependent diabetes mellitus - Diabetic retinopathy
11.2
6.8
12
11
D01BA02
ATC
terbinafine; oral; topical
1.9
6.8
113
678
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.1
6.8
78
406
L24.8
ICD-10 Finland
Irritant contact dermatitis due to other agents
40.7
6.8
8
*
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
17.0
6.8
10
6
SPAT1305
SPAT
Counselling and guidance related to physical exercise
2.5
6.8
53
230
SPAT1147
SPAT
Destruction of skin lesion with external methods
7.4
6.8
15
21
S81.8
ICD-10 Finland
Open wound of other parts of lower leg
4.6
6.7
22
50
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.3
6.7
65
313
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.7
6.7
199
1437
L89
ICD-10 Finland
Decubitus ulcer and pressure area
22.9
6.7
9
*
M13.9
ICD-10 Finland
Arthritis, unspecified
2.9
6.7
39
143
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.1
6.6
35
121
H3603, E103
ICD-10 Finland
NA
10.2
6.6
12
12
QBE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin of trunk
3.0
6.5
37
132
A98
ICPC
Health maint/preventive medicine
2.4
6.5
409
3715
J01DA01
ATC
[U] cefalexin; systemic
1.7
6.4
268
2123
K07.60
ICD-10 Finland
Snapping jaw
3.8
6.4
25
68
SPAT1043
SPAT
Audiometry
2.3
6.3
56
259
C03DA01
ATC
spironolactone; oral
2.3
6.3
60
285
C08CA05
ATC
nifedipine; systemic
2.7
6.3
41
160
L21.0
ICD-10 Finland
Seborrhoea capitis
11.2
6.3
11
10
K59.09
ICD-10 Finland
Constipation, unspecified
2.9
6.3
37
136
290
Kela drug reimbursment
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
2.1
6.3
77
412
Z49.2
ICD-10 Finland
Other dialysis
18.3
6.3
9
5
XQ802
NOMESCO Finland
Epicutan test
4.1
6.3
23
59
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
4.1
6.3
23
59
N02AX02
ATC
tramadol; systemic, rectal
1.7
6.3
188
1350
PG5RT
NOMESCO Finland
PTA of arterio-venous shunt for dialysis
+∞
6.3
6
*
L93.0
ICD-10 Finland
Discoid lupus erythematosus
+∞
6.3
6
*
E10.9
ICD-10 Finland
Type 1 diabetes mellitus, Without complications
3.5
6.2
27
80
PD4DG
NOMESCO Finland
Very extensive MRI examination of abdominal aortta and vasculature of lower extremities with high intensity magnet
27.1
6.2
8
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.0
6.2
80
435
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.6
6.2
20
45
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.6
6.2
26
75
D22.5
ICD-10 Finland
Melanocytic naevi of trunk
3.6
6.2
26
75
I50.1
ICD-10 Finland
Left ventricular failure
3.2
6.2
30
97
SPAT1229
SPAT
Assessment of need for aid
2.6
6.2
46
192
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.7
6.2
155
1058
C01DA14
ATC
isosorbide mononitrate; oral
2.0
6.2
87
490
8090/3-C44.5
ICD-O-3
Basal cell carcinoma, NOS, of skin of trunk
5.9
6.2
16
28
A07AA02
ATC
nystatin; oral
3.0
6.2
35
124
S01
ICPC
Pain/tenderness of skin
3.6
6.1
26
76
SPAT1262
SPAT
Handing over of treatment supplies
2.0
6.1
86
482
A06AC01
ATC
ispaghula (psylla seeds); oral
1.8
6.0
110
677
QX2XE
NOMESCO Finland
Ultrsound examination of soft tissue not elsewhere classified
4.7
6.0
19
42
D06BB10
ATC
imiquimod; topical
3.3
6.0
28
88
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
195
508
5.61
74.27
18.3
7.1
—
—
—
0
0
135
384
4.43
43.80
2.9
2.4
6.5
7.4
ug/l
0.16
120
336
112
302
4.47
38.62
3.0
2.7
54.6
63.9
ml/min/173m2
1.99
61
127
209
899
3.25
35.56
7.9
4.1
1.0
1.0
kg/l
0.10
13
133
383
2365
3.52
34.31
12.0
8.7
4.2
4.2
e9/l
0.11
360
2073
150
541
3.52
33.79
8.7
5.2
1.1
1.0
mmol/l
2.16
140
493
313
1836
2.84
28.41
6.2
4.5
34.6
35.2
g/l
0.98
294
1702
224
1110
2.82
28.19
7.9
4.0
0.0
0.0
estimate
0.50
28
370
217
1088
2.74
26.29
3.2
2.2
3.2
3.1
mg/l
0.18
190
931
108
368
3.46
26.02
2.1
2.9
65.3
66.3
g/l
0.76
100
337
96
321
3.45
23.69
4.3
3.7
101.4
84.9
ng/l
0.90
89
283
318
1999
2.58
23.23
7.0
3.7
0.0
0.0
estimate
0.00
31
384
237
1312
2.51
22.58
3.9
2.5
55.0
57.2
u/l
0.48
216
1209
246
1390
2.49
22.36
5.0
3.1
2196.1
1401.5
ng/l
1.20
224
1193
232
1277
2.50
22.32
2.6
2.1
328.3
274.8
u/l
0.10
220
1195
124
501
2.95
22.14
6.5
8.2
4.9
5.1
kpa
1.21
118
481
124
501
2.95
22.14
6.4
8.3
1.7
1.4
mmol/l
0.45
88
396
319
2036
2.52
22.12
7.0
3.8
0.0
0.0
estimate
0.00
28
372
124
502
2.94
22.05
6.5
8.2
11.1
11.9
kpa
1.40
117
485
154
703
2.71
21.78
3.5
2.4
11.5
12.9
umol/l
1.71
144
644
204
1088
2.46
20.67
4.1
2.7
366.6
8438.2
umol/l
5.43
177
923
310
2002
2.41
20.20
7.9
5.0
0.0
0.0
estimate
0.00
28
381
413
3055
2.88
19.95
6.5
4.1
15.2
12.8
mm/h
2.13
392
2798
118
493
2.82
19.60
6.0
3.9
234.8
244.7
u/l
0.59
110
466
359
2498
2.49
19.43
7.6
4.9
6.9
6.7
mmol/l
0.74
344
2345
271
1671
2.33
19.37
5.5
3.8
48.7
56.6
ng/l
0.14
221
1246
257
1555
2.32
19.14
7.5
3.9
—
—
—
0
0
318
2108
2.36
19.05
11.4
6.6
1.2
1.2
mmol/l
3.87
293
1771
298
1937
2.30
18.48
10.3
6.0
1.2
1.2
mmol/l
3.99
280
1738
34
61
5.90
18.45
6.4
6.8
399.3
287.3
iu/ml
—
7
10
138
644
2.57
18.28
3.6
2.3
2.3
2.3
g/l
0.75
131
591
267
1670
2.26
18.02
2.8
2.2
74.8
77.3
nmol/l
0.79
244
1467
325
2217
2.29
17.59
7.9
6.2
13.6
11.7
umol/l
0.49
311
2102
417
3181
2.74
17.44
11.5
7.4
80.7
78.9
u/l
0.33
405
2976
99
403
2.81
17.11
6.1
3.5
2.3
2.0
mmol/l
0.35
80
319
250
1565
2.18
16.34
5.8
3.2
—
—
—
0
0
377
2788
2.37
16.11
7.4
4.6
8.3
3035.7
e6/l
—
7
51
402
3065
2.49
15.90
4.8
3.8
15.2
14.8
pmol/l
2.27
370
2744
274
1792
2.15
15.83
2.4
2.0
92.4
95.1
pmol/l
0.39
166
936
126
609
2.42
15.19
3.6
2.4
20.9
22.1
%
0.46
108
517
124
596
2.43
15.12
42.2
24.9
1.2
1.3
inr
0.32
18
85
263
1722
2.09
14.83
4.2
2.8
143.8
131.3
ug/l
0.45
245
1575
135
681
2.34
14.72
4.9
3.5
0.8
0.8
mmol/l
0.19
121
637
159
865
2.22
14.44
1.8
1.8
1635.7
1184.7
nmol/l
4.17
126
650
231
1457
2.07
14.24
3.1
3.2
2.3
2.3
mmol/l
1.11
199
1265
25
43
6.06
14.12
2.4
2.5
—
—
—
0
0
214
1326
2.06
13.71
3.9
3.1
6.8
7.5
mmol/l
1.93
186
1081
75
296
2.80
13.60
2.3
1.5
—
—
—
0
0
22
35
6.52
13.38
1.3
1.3
15802.3
128411.7
e6/l
0.63
15
22
40
112
3.79
12.69
1.9
1.9
—
—
—
0
0
136
738
2.15
12.16
2.3
1.8
—
—
—
0
0
64
246
2.83
12.16
1.6
1.5
—
—
—
0
0
105
520
2.28
11.72
2.3
1.8
—
—
—
0
0
104
516
2.28
11.54
2.1
1.8
—
—
—
0
0
39
118
3.50
11.05
1.7
1.1
—
—
—
0
0
442
3711
2.47
11.02
6.2
4.7
2.0
1.9
mu/l
0.69
417
3350
206
1341
1.90
10.82
4.6
4.0
23.6
9.0
mg/mmol
1.46
161
840
36
106
3.58
10.62
2.2
2.8
306.4
64.4
ug/min
1.08
25
63
131
744
2.03
10.17
3.3
2.9
1.4
1.1
e6/l
0.56
97
433
22
46
4.95
10.10
1.0
1.2
1.6
1.5
g/l
0.08
22
41
25
59
4.40
9.95
1.6
1.4
126.2
102.2
u/ml
—
9
10
464
4037
2.72
9.77
31.6
15.0
24.8
25.2
mg/l
0.07
417
3243
46
167
2.93
9.67
1.6
2.5
9.2
10.3
g/l
1.07
37
145
31
89
3.64
9.50
1.5
1.4
—
—
—
0
0
140
832
1.94
9.46
1.5
1.2
0.9
1.3
u/ml
0.60
37
208
26
66
4.10
9.43
1.7
1.4
—
—
—
0
0
48
182
2.81
9.33
1.6
2.4
3.6
3.7
g/l
0.23
36
134
141
844
1.93
9.31
2.8
3.1
2.4
2.4
mmol/l
0.05
128
747
172
1100
1.85
9.25
1.8
1.6
18.2
20.5
nmol/l
1.24
152
932
48
183
2.79
9.23
1.6
2.4
—
—
—
0
0
48
183
2.79
9.23
1.6
2.4
6.9
7.4
g/l
1.24
36
142
46
172
2.84
9.17
1.6
2.5
2.9
3.2
g/l
0.73
36
136
25
63
4.12
9.16
1.2
1.3
—
—
—
0
0
146
894
1.89
8.95
2.5
1.7
1.1
1.3
mg/l
0.50
115
695
439
3764
2.22
8.92
8.6
6.1
42.5
40.2
mmol/mol
3.41
419
3473
24
60
4.15
8.88
1.3
1.3
327.2
288.1
u/ml
0.22
17
36
443
3817
2.26
8.81
5.5
4.1
1.4
1.3
mmol/l
1.68
403
3449
15
25
6.15
8.70
1.2
1.2
—
—
—
0
0
473
4205
2.81
8.58
35.6
17.8
139.2
139.7
mmol/l
3.38
468
4088
479
4290
3.04
8.48
17.6
10.5
25.3
25.0
u/l
0.17
469
4120
473
4211
2.79
8.44
35.7
17.9
4.0
4.0
mmol/l
3.48
467
4090
77
383
2.19
8.37
2.2
2.3
0.2
0.2
g/l
1.31
66
353
13
20
6.64
8.10
1.7
1.3
18.2
19.0
umol/l
0.03
13
20
149
946
1.81
8.02
1.6
1.7
160769662.3
436.9
pmol/l
0.79
130
775
15
28
5.49
7.77
1.2
1.2
—
94.4
—
0
5
34
121
2.94
7.42
1.5
1.2
—
—
—
0
0
451
3985
2.17
7.25
6.1
4.5
4.3
4.6
mmol/l
4.58
412
3650
34
123
2.89
7.21
1.5
1.2
—
—
—
0
0
457
4074
2.21
6.93
6.6
5.1
2.5
2.7
mmol/l
2.32
420
3720
31
110
2.94
6.81
1.5
1.2
—
—
—
0
0
446
3950
2.06
6.72
5.9
4.5
1.4
1.5
mmol/l
3.55
405
3593
254
1947
1.61
6.44
5.3
4.1
—
—
—
0
0
37
150
2.58
6.34
1.7
2.6
37.2
37.7
g/l
0.19
30
130
484
4459
2.81
6.18
45.2
22.3
130.5
134.6
g/l
6.49
479
4380
30
113
2.76
5.94
1.7
1.6
—
—
—
0
0
14
32
4.47
5.80
2.0
1.8
417.7
763.1
e6/l
—
6
13
442
3961
1.89
5.57
6.4
4.8
6.3
6.0
mmol/l
2.68
412
3597
281
2259
1.55
5.45
3.3
2.8
—
—
—
0
0
147
1020
1.62
5.43
3.1
2.4
—
—
—
0
0
37
162
2.38
5.42
2.0
2.7
0.3
0.7
g/l
0.50
29
145
10
18
5.65
5.34
1.4
1.2
—
—
—
0
0
8
6
13.52
5.09
1.0
1.0
—
—
—
0
0
18
55
3.36
5.07
1.7
1.5
—
—
—
0
0
166
1214
1.55
4.81
4.5
3.3
0.6
0.5
e6/l
0.21
139
924
28
114
2.54
4.80
1.3
1.4
238.3
281.4
ug/g
0.48
16
68
16
48
3.41
4.64
1.4
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
31
138
2.33
4.41
6.5
2.9
0.3
0.4
u/ml
1.22
15
78
166
1239
1.50
4.29
5.7
4.5
23.2
21.0
%
1.06
84
605
12
31
3.94
4.28
1.1
1.2
—
—
—
0
0
37
184
2.09
4.05
1.5
1.3
—
—
—
0
0
20
75
2.73
4.04
2.0
1.6
—
—
—
0
0
25
106
2.43
3.97
1.5
1.7
—
—
—
0
0
23
94
2.52
3.94
1.5
1.3
—
—
—
0
0
119
842
1.54
3.91
6.0
4.0
672.1
264.5
ng/l
0.52
92
678
24
101
2.44
3.87
1.9
1.6
—
—
—
0
0
23
97
2.44
3.70
2.0
1.6
—
—
—
0
0
22
91
2.48
3.69
1.5
1.4
230.0
262.0
miu/ml
—
6
41
13
40
3.31
3.65
2.2
1.6
—
—
—
0
0
13
40
3.31
3.65
2.2
1.6
—
—
—
0
0
13
40
3.31
3.65
2.2
1.6
—
—
—
0
0
20
81
2.53
3.50
1.2
1.4
—
—
—
0
0
32
161
2.05
3.42
2.0
2.2
41.7
39.0
u/l
0.24
32
142
94
665
1.51
3.06
1.3
1.3
23.1
36.8
iu/ml
1.07
22
215
298
2582
1.37
3.05
3.8
3.2
68.6
50.7
u/l
1.56
274
2391
13
45
2.94
3.04
2.0
1.6
—
—
—
0
0
29
148
2.02
3.01
2.4
2.8
—
—
—
0
0
31
163
1.96
2.97
2.1
1.6
—
—
—
0
0
83
577
1.52
2.93
1.4
1.5
—
—
—
0
0
58
372
1.63
2.88
2.2
1.9
375.9
386.3
nmol/l
0.14
53
342
33
180
1.89
2.85
2.3
1.8
—
—
—
0
0
37
210
1.82
2.83
10.6
4.0
24.4
24.3
mmol/l
0.02
25
191
13
48
2.75
2.73
2.0
1.6
—
—
—
0
0
13
48
2.75
2.73
1.2
1.1
—
—
—
0
0
22
105
2.14
2.73
2.2
2.2
13.5
13.1
mg/l
0.06
22
96
17
73
2.37
2.68
1.5
1.5
—
—
—
0
0
7
15
4.72
2.60
1.0
1.0
—
—
—
0
0
69
473
1.53
2.60
3.4
2.9
8.3
8.5
umol/l
0.02
61
413
33
186
1.83
2.60
1.0
1.0
—
—
—
0
0
69
474
1.53
2.58
1.6
1.4
—
—
—
0
0
15
62
2.46
2.56
1.6
1.5
—
—
—
0
0
15
62
2.46
2.56
9.3
6.2
12.3
11.4
mg/l
0.39
15
56
6
11
5.50
2.55
1.2
1.0
2002.3
1654.6
miu/ml
—
6
11
20
95
2.15
2.52
1.4
1.4
—
—
—
0
0
15
63
2.42
2.48
1.5
1.5
—
—
—
0
0
86
626
1.45
2.43
1.3
1.3
16.7
9.8
u/ml
0.33
39
220
20
97
2.11
2.40
1.3
1.1
—
—
—
0
0
9
27
3.37
2.40
1.9
1.4
0.3
0.2
e9/l
—
9
21
14
58
2.45
2.39
1.1
1.0
—
—
—
0
0
11
40
2.79
2.39
1.1
1.5
0.2
0.3
nmol/l
—
6
29
38
230
1.70
2.37
3.0
2.8
0.6
0.3
e6/l
0.24
38
225
9
28
3.25
2.31
1.9
1.4
480.7
527.3
e6/l
—
9
21
187
1558
1.32
2.29
5.2
5.3
1.6
2.6
ug/l
3.13
168
1379
12
47
2.59
2.28
2.6
2.3
—
—
—
0
0
6
13
4.66
2.27
1.8
1.2
—
—
—
0
0
22
114
1.97
2.24
1.5
1.5
—
—
—
0
0
388
3581
1.35
2.21
25.4
16.6
39.5
39.5
%
0.00
198
2441
408
3809
1.36
2.04
23.3
14.4
71.0
77.4
ml/min/173m2
5.47
331
3135
9
32
2.84
2.01
1.8
1.1
—
—
—
0
0
8
27
2.99
1.94
3.5
4.3
—
—
—
0
0
7
22
3.21
1.88
1.1
1.5
—
—
—
0
0
5
12
4.20
1.82
1.0
1.1
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
23
3.07
1.80
1.1
1.1
—
—
—
0
0
85
1084
0.74
1.76
2.0
1.6
1.4
1.3
mmol/l
0.23
77
897
7
24
2.94
1.73
1.6
2.5
13.4
13.5
%
—
7
24
17
89
1.94
1.72
1.2
1.2
15.3
7.4
u/l
1.08
11
66
18
97
1.89
1.68
1.3
1.1
—
3.4
—
0
8
36
238
1.55
1.65
1.5
1.2
110.2
120.6
iu/ml
0.07
17
94
5
14
3.60
1.62
1.0
1.4
—
—
—
0
0
34
223
1.56
1.61
2.9
2.9
4.0
4.5
pmol/l
1.31
28
200
6
20
3.02
1.58
1.2
1.1
—
—
—
0
0
8
33
2.45
1.54
1.0
1.4
—
—
—
0
0
19
110
1.76
1.45
1.7
1.6
—
—
—
0
0
5
16
3.15
1.44
2.2
1.7
—
—
—
0
0
5
16
3.15
1.44
3.6
3.9
89.8
103.8
%
—
5
16
9
40
2.27
1.40
1.0
1.1
—
—
—
0
0
7
29
2.43
1.39
1.0
1.0
—
—
—
0
0
11
53
2.10
1.39
1.1
1.2
14.2
8.0
u/ml
—
5
24
9
41
2.22
1.37
1.0
1.0
—
—
—
0
0
11
55
2.02
1.28
1.7
1.5
—
—
—
0
0
10
51
1.98
1.12
1.2
1.3
—
—
—
0
0
7
31
2.28
1.10
1.0
1.4
—
—
—
0
0
5
21
2.39
1.09
1.6
1.6
—
—
—
0
0
16
97
1.67
1.08
2.8
1.7
2.8
6.5
iu/l
—
8
24
73
888
0.79
1.06
2.7
3.1
0.5
0.8
ug/l
4.78
57
596
9
46
1.97
1.04
1.7
1.6
—
—
—
0
0
147
1296
1.19
0.99
4.4
3.3
32.8
32.0
u/l
0.11
142
1231
9
50
1.81
0.97
1.1
1.0
—
—
—
0
0
51
401
1.30
0.97
1.6
1.8
1.5
1.5
%
0.02
44
351
10
55
1.83
0.92
1.0
1.1
—
58.0
—
0
10
15
94
1.61
0.91
1.1
1.4
—
—
—
0
0
15
94
1.61
0.91
1.1
1.4
—
—
—
0
0
58
470
1.26
0.88
3.8
4.2
5.5
32.9
ug/l
1.01
51
404
36
274
1.34
0.86
2.0
1.7
—
—
—
0
0
19
270
0.69
0.81
2.0
1.7
—
—
—
0
0
6
34
1.77
0.76
1.2
1.1
—
—
—
0
0
6
34
1.77
0.76
1.2
1.1
—
—
—
0
0
6
34
1.77
0.76
1.2
1.1
—
—
—
0
0
9
53
1.71
0.75
1.9
1.3
—
—
—
0
0
9
54
1.68
0.75
1.9
1.3
—
—
—
0
0
9
54
1.68
0.75
1.9
1.3
—
—
—
0
0
5
24
2.09
0.74
1.6
1.1
—
—
—
0
0
5
24
2.09
0.74
1.6
1.1
—
—
—
0
0
9
55
1.65
0.74
1.9
1.3
—
—
—
0
0
9
55
1.65
0.74
1.9
1.3
—
—
—
0
0
9
55
1.65
0.74
1.9
1.3
—
—
—
0
0
5
26
1.93
0.71
1.0
1.5
—
—
—
0
0
5
26
1.93
0.71
1.0
1.5
—
—
—
0
0
7
41
1.72
0.70
2.0
1.7
—
—
—
0
0
13
85
1.54
0.69
1.6
1.5
—
—
—
0
0
13
85
1.54
0.69
2.7
2.3
18.1
16.1
%
—
7
37
5
27
1.86
0.68
1.2
1.6
—
—
—
0
0
5
28
1.79
0.66
1.2
1.2
—
—
—
0
0
14
96
1.47
0.62
1.1
1.2
—
—
—
0
0
25
317
0.78
0.56
3.4
2.2
—
—
—
0
0
6
37
1.63
0.55
2.0
1.9
—
—
—
0
0
36
300
1.22
0.48
1.8
2.3
12.1
12.7
nmol/l
0.17
30
256
14
104
1.36
0.43
1.3
1.5
—
—
—
0
0
14
105
1.34
0.41
1.3
1.2
—
—
—
0
0
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
5
33
1.52
0.41
1.6
1.6
—
—
—
0
0
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
5
33
1.52
0.41
1.0
1.1
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
402.5
—
0
11
9
70
1.29
0.37
1.2
1.5
—
—
—
0
0
32
275
1.17
0.33
5.2
3.3
1.0
2.0
mmol/l
1.35
26
198
7
97
0.72
0.31
1.0
1.5
—
—
—
0
0
22
185
1.20
0.29
6.0
3.6
23.9
25.0
mmol/l
1.44
22
174
7
61
1.15
0.17
1.0
1.2
—
—
—
0
0
26
287
0.90
0.16
3.0
2.0
—
—
—
0
0
58
550
1.06
0.13
5.2
4.5
32.7
32.3
%
0.11
38
357
74
711
1.05
0.11
3.7
3.1
2.2
2.4
e6/l
0.10
45
403
6
55
1.09
0.09
1.0
1.1
—
—
—
0
0
44
449
0.98
0.02
4.3
3.5
—
—
—
0
0
17
164
1.04
0.00
2.3
2.2
—
—
—
0
0
13
129
1.01
0.00
2.3
2.1
—
—
—
0
0
0
9
0.00
0.00
0.0
2.9
—
—
—
0
0
0
9
0.00
0.00
0.0
2.9
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
95.0
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
3.1
—
93.4
—
0
7
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
6
60
1.00
0.00
3.5
3.5
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_XEROSCUT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_XEROSCUT | 1.673 [1.27, 2.2] | < 0.001 |
| Birth year | 0.99 [0.98, 1.0] | 0.023 |
During the follow-up period (1.1.1998 — 31.12.2019), 223 out of 875 females with L12_XEROSCUT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_XEROSCUT | 2.043 [1.5, 2.79] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.012 |
During the follow-up period (1.1.1998 — 31.12.2019), 277 out of 820 males with L12_XEROSCUT died.
Mortality risk
Mortality risk for people of age
years, who have L12_XEROSCUT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.113% | 0.411% |
| 5 | 0.808% | 2.582% |
| 10 | 2.019% | 6.221% |
| 15 | 3.996% | 12.021% |
| 20 | 7.158% | 19.296% |
Relationships between endpoints
↥Index endpoint: L12_XEROSCUT – Xerosis cutis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data